NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2031210172

Registered date:29/06/2021

ONO-7913-03: ONO-7913 Phase 1 Study

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedUntreated metastatic pancreatic cancer
Date of first enrollment30/07/2021
Target sample size30
Countries of recruitment
Study typeInterventional
Intervention(s)Administration of ONO-7913 and ONO-4538 in combination with mFFX therapy

Outcome(s)

Primary OutcomeTolerability, safety
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteria1. Untreated metastatic pancreatic cancer 2. Life expectancy of at least 3 months 3. Patients with ECOG performance status 0 or 1
Exclude criteria1. Patients with severe complication 2. Patients with multiple primary cancers

Related Information

Contact

Public contact
Name Medical Information Center
Address 3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan Osaka Japan 618-8585
Telephone +81-120626190
E-mail clinical_trial@ono-pharma.com
Affiliation Ono Pharmaceutical Co.,LTD
Scientific contact
Name Yoshinori Hirashima
Address 3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan Osaka Japan 618-8585
Telephone +81-120626190
E-mail clinical_trial@ono-pharma.com
Affiliation Ono Pharmaceutical Co.,LTD